

 Substitute Form PTO-1449 (Modified) <b>Information Disclosure Statement</b> by Applicant (Use several sheets if necessary) 37 CFR §1.98(b)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 16743-003001 / 12A-920716	Application No. 10/705,245
	Applicant Chen, et al.		
	Filing Date November 10, 2003	Group Art Unit Unknown	

**U.S. Patent Documents**

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
STK	AA	6,583,139	06/24/2003	Thorsett, et al.			
	AB						
	AC						
	AD						

**Foreign Patent Documents or Published Foreign Patent Applications**

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	AE							
	AF							
	AG							
	AH							

**Other Documents (include Author, Title, Date, and Place of Publication)**

Examiner Initial	Desig. ID	Document
STK	AI	Bigby M, Jick S, Jick H, Amdt K. (1986) Drug-induced cutaneous reactions. A report from the Boston Collaborative Drug Surveillance Program on 15,438 consecutive inpatients, 1975 to 1982. <i>JAMA</i> . 256(24):3358-3363.
	AJ	Chan SH and Tan T. "HLA and allopurinol drug eruption" <i>Dermatologica</i> . 1989, 179(1):32-3.
	AK	Edwards SG, Hubbard V, Aylett S, Wren D. Concordance of primary generalised epilepsy and carbamazepine hypersensitivity in monozygotic twins. <i>Postgrad Med J</i> . 1999, 75(889):680-1.
	AL	Feltkamp TE, Mardjuadi A, Huang F, Chou CT. Spondyloarthropathies in eastern Asia. <i>Curr Opin Rheumatol</i> . 2001, 13(4):285-90.
	AM	Gennis MA, Vernuri R, Burns EA, Hill JV, Miller MA, Spielberg SP. Familial occurrence of hypersensitivity to phenytoin. <i>Am J Med</i> . 1991, 91(6):631-4.
	AN	Green VJ, Pirmohamed M, Kitteringham NR, Gaedigk A, Grant DM, Boxer M, Burchell B, Park BK. Genetic analysis of microsomal epoxide hydrolase in patients with carbamazepine hypersensitivity. <i>Biochem Pharmacol</i> . 1995, 50(9):1353-9.
	AO	Hari Y, Frutig-Schnyder K, Humi M, Yawalkar N, Zanni MP, Schnyder B, Kappeler A, von Greysen S, Braathen LR, Pichler WJ. T cell involvement in cutaneous drug eruptions. <i>Clin Exp Allergy</i> . 2001, 31(9):1398-408.
	AP	Khan MA. Update: the twenty subtypes of HLA-B27. <i>Curr Opin Rheumatol</i> . 2000;12(4):235-8.
	AQ	Lazarou J, Pomeranz BH, Corey PN. (1998) Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. <i>JAMA</i> . 279(15):1200-1205.

Examiner Signature /Stephen Kapushoc/	Date Considered 05/10/2006
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office		Attorney's Docket No. 16743-003001 / 12A-920716	Application No. 10/705,245
Information Disclosure Statement by Applicant (Use several sheets if necessary)				Applicant Chen, et al.	
Filing Date November 10, 2003				Group Art Unit Unknown	
Other Documents (include Author, Title, Date, and Place of Publication)					
Examiner Initial	Desig. ID	Document			
STK	AR	Leeder JS. Mechanisms of idiosyncratic hypersensitivity reactions to antiepileptic drugs. <i>Epilepsia</i> . 1998, 39 Suppl 7:S8-16.			
	AS	Naisbitt DJ, Britschgi M, Wong G, Farrell J, Depta JP, Chadwick DW, Pichler WJ, Pirmohamed M, Park BK. Hypersensitivity reactions to carbamazepine: characterization of the specificity, phenotype, and cytokine profile of drug-specific T cell clones. <i>Mol Pharmacol</i> . 2003, 63(3):732-41.			
	AT	Pichler WJ, Zanni M, von Greysen S, Schnyder B, Mauri-Hellweg D, Wendland T. High IL-5 production by human drug-specific T cell clones. <i>Int Arch Allergy Immunol</i> . 1997, 113(1-3):177-80.			
	AU	Pirmohamed M, Lin K, Chadwick D, Park BK. TNF $\alpha$ promoter region gene polymorphisms in carbamazepine-hypersensitive patients. <i>Neurology</i> . 2001, 56(7):890-6.			
	AV	Roujeau JC, Bracq C, Huynh NT, Chaussat E, Raffin C, Duedari N. HLA phenotypes and bullous cutaneous reactions to drugs. <i>Tissue Antigens</i> . 1986, 28(4):251-4.			
	AW	Roujeau JC, Huynh TN, Bracq C, Guillaume JC, Revuz J, Touraine R. Genetic susceptibility to toxic epidermal necrolysis. <i>Arch Dermatol</i> . 1987, 123(9):1171-3.			
	AX	Roujeau JC. The spectrum of Stevens-Johnson syndrome and toxic epidermal necrolysis: a clinical classification. <i>J Invest Dermatol</i> . 1994, 102(6):28S-30S.			
	AY	Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. <i>N Engl J Med</i> . 1994, 331(19):1272-85.			
	AZ	Roujeau JC, Kelly JP, Naldi L, Rzany B, Stern RS, Anderson T, Auquier A, Bastuji-Garin S, Correia O, Locati F, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. <i>N Engl J Med</i> . 1995, 333(24):1600-7.			
	AAA	Shirato S, Kagaya F, Suzuki Y, Joukou S. Stevens-Johnson syndrome induced by methazolamide treatment. <i>Arch Ophthalmol</i> . 1997, 115(4):550-3.			
	ABB	Svensson CK, Cowen EW, Gaspari, AA. (2000) Cutaneous drug reactions. <i>Pharmacol Rev</i> . 53(3):357-379.			
	ACC	Wolkenstein P, Carriere V, Charue D, Bastuji-Garin S, Revuz J, Roujeau JC, Beaune P, Bagot M. A slow acetylator genotype is a risk factor for sulphonamide-induced toxic epidermal necrolysis and Stevens-Johnson syndrome. <i>Pharmacogenetics</i> . 1995, 5(4):255-8.			
	ADD	Yates CR, Krynetski EY, Loennechen T, Fessing MY, Tai HL, Pui CH, Relling MV, Evans WE. Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. <i>Ann Intern Med</i> . 1997, 126(8):608-14.			

Examiner Signature /Stephen Kapushoc/	Date Considered 05/10/2006
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	